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Abstract One of the main aims of synthetic biology is to
make biology easier to engineer. Major efforts in synthetic
biology are made to develop a toolbox to design biological
systems without having to go through a massive research
and technology process. With this ‘‘de-skilling’’ agenda,
synthetic biology might ﬁnally unleash the full potential of
biotechnology and spark a wave of innovation, as more and
more people have the necessary skills to engineer biology.
But this ultimate domestication of biology could easily lead
to unprecedented safety challenges that need to be
addressed: more and more people outside the traditional
biotechnology community will create self-replicating
machines (life) for civil and defence applications, ‘‘bio-
hackers’’ will engineer new life forms at their kitchen table;
and illicit substances will be produced synthetically and
much cheaper. Such a scenario is a messy and dangerous
one, and we need to think about appropriate safety stan-
dards now.
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‘‘My motivation is that years from now, anybody who
wants to [can] dream up a useful biological system
and pull it off, without having to go through this
whole big research process to do it’’
Drew Endy 2007
1
‘‘Some people would argue that we should not worry
about that [spreading of the capability and technol-
ogy of synthetic biology], that the best thing we can
do is to spread this capability as widely as possible
and then in some way I don’t quite understand
everything will be made safe. To my mind that’s
exactly the wrong way to go.’’
Malcom Dando 2007
2
Background
Fast becoming one of the most dynamic new science and
engineering ﬁelds, synthetic biology has the potential to
impact many areas of society. Synthetic biologists use
artiﬁcial molecules to reproduce emergent behaviour from
natural biology, with the goal of creating artiﬁcial life or
seek interchangeable biological parts to assemble them into
devices and systems that function in a manner not found in
nature (Benner and Sismour 2005; Endy 2005; Heinemann
and Panke 2006; Luisi 2007; Serrano 2007). Approaches
from synthetic biology, in particular the deliberate syn-
thesis of complex, biological systems, have the capacity to
change the way we approach many key technologies and
biotechnology applications.
Knowledgeonthedesignprinciplesofbiologicalsystems
becomes easier to understand, and fabrication capabilities
are ever more powerful and ubiquitous. Tasks such as
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becarriedoutatleastbypost-docscientistscannowbedone
by technical assistants or are outsourced to automated
machines altogether. The increase in production capabilities
for sequencing and synthesizing has already been compared
to Moore’s law in microelectronics (Carlson 2003; Carlson
2007a; Gibson et al. 2008). Advances in technological
capabilities regarding synthesising and sequencing are
accompanied by attempts to convert biology into a true
engineering discipline with characteristics such as in silico
testing of models, setting up hierarchies of abstraction,
standardisation and interchangeability, and the decoupling
of design and fabrication (Heinemann and Panke 2006). If
successful these changes will further facilitate the rational
use of biological systems. Also it will enlarge the circle of
people who have the necessary skills to engineer biology.
The iGEM student contest
3 for the design of genetically
engineered machines, for examples, gathers undergraduate
students from various disciplines including students from
non-biological disciplines such as engineering or informat-
ics. Its aim is to promote the use of standardized biological
parts and to increase the number of useful parts in order to
makeiteasierandmoreinterestingtodesignnovelanduseful
organisms.Diffusionofsyntheticbiology,inotherwordsthe
easy access and the simplicity to use it, would automatically
create an unprecedented biosafety challenge.
Newcomers and laboratory safety
Synthetic biology is a real interdisciplinary ﬁeld, involving
chemists, biologists, engineers, physicists or computer
scientists. Some of those communities and practitioners of
synthetic biology are generally educated in disciplines that
do not routinely include formal biosafety training. As the
growing interest in synthetic biologist attracts a number of
non-biotechnologists to the ﬁeld, the amount of newcomers
untrained in biosafety rules increases as well. In a recent
policy paper on synthetic genomics (Garﬁnkel et al. 2007)
some governance options were presented that could help to
targeting this phenomena:
• Include biosafety training as part of an interdisciplinary
education in synthetic biology, dealing with risks and
best practices as part of college and university curric-
ula, critical for at least priming these newcomers to the
safety challenges in synthetic biology
• Preparation of a biosafety manual for synthetic biology
laboratories, distinct from those manuals already
available
• Broaden Institutional Biosafety Committees (IBC)
review plus enhanced oversight and/or enforcement
These, and other strategies may handle the possible
problem related to the fact that many new researchers with
a professional background other than biology are unskilled
in the handling of (dangerous) biological material in the
laboratory. These strategies are, however, practically use-
less if the newcomers are not working in a professional
setting and are not accountable to a public authority, as is
the case with so-called biohackers.
Biohackery, garage biology, do-it-yourself biology
The more biology becomes an information science the
more computer software scenarios become possible within
biology. It is little surprise that some people from the IT/
engineering community aware of recent developments in
synthetic biology foresee a development were computer
scientists and/or hackers could turn their interest to biology
(see: Hanson 2004; Counsell 2001; Anonymous 2003;
Endy 2007). Also it is likely that in the future more and
more people without a traditional education in biology or
genetics (and probably even without higher education) will
be able to manufacture biological systems. Synthetic
biology could thus give rise to a new kind of hacker cul-
ture, the ‘‘biohacker’’. Biohackery means designing and
manufacturing biological systems in an open way but
without hardly any kind of regulatory oversight or
enforcement in place. Although the number of such bio-
hackers might be quite limited, it doesn’t take a lot to
become one and a few rather low-tech do-it-yourself DNA
hacking documents are already available in the web.
4
Recently the do-it-yourself biology (DIY-Bio) online dis-
cussion group was launched
5 and motivated biohackers
already held their ﬁrst physical meeting in Boston, in May
2008. A young crowd of enthusiastic biohackers may well
follow the example of the ‘‘Homebrew Computer Club’’
from the mid 1970s, and a true biohacker community might
spark a wave of innovation unseen in cooperate research
programs. Facilitating everybody to construct new life
forms or biological systems, however, also creates an
inherent biosafety (and biosecurity) risk. Imaging a world
where practically anybody with an average IQ would have
the ability to create novel organisms in their home garage
3 The International Genetically Engineered Machine Competition,
carried out by MIT and the Biobricks foundation. See e.g.
http://parts.mit.edu/igem07/
4 See e.g.: http://biohack.sourceforge.net/ This open, free synthetic
biology kit contains all sorts of information from across the web on
how to do it: how to extract and amplify DNA, cloning techniques,
making DNA by what’s known as oligonucleotides, and all sorts of
other tutorials and documents on techniques in genetic engineering,
tissue engineering, synthetic biology, stem cell research, SCNT,
evolutionary engineering, bioinformatics, etc.
5 See: http://groups.google.com/group/diybio/
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reporting system and lacking a sufﬁcient biosafety training,
is a thrilling thought.
It is true that there is a kind of informal code of ethics
for the hacker community
6 that demands to ‘‘be safe, do not
damage anything, do not damage anyone, either physically,
mentally or emotionally, be funny, at least to most of the
people who experience it’’. This hacker ethics, however,
did not and could not prevent the tons of malware pro-
grammes out there in the worldwideweb. The more
successful the attempts to program DNA as a 2 bit lan-
guage for engineering biology become (Endy 2007) the
more likely will be the appearance of ‘‘bio-spam, bio-
spyware, bio-adware’’ and other bio-nuisances. An unre-
stricted biohackery scenario could put the health of a
biohacker, the community around him or her and the
environment under unprecedented risk. This scenario has
not gone totally unnoticed in the biohacker community and
some have started to show at least some interest in safety
issues, asking e.g. ‘‘how to use a pressure-cooker as an
autoclave’’ or thinking to obtain some lab safety videos.
7
Illicit bio-economy
In contrast to a biohackery scenario that is driven largely
by curiosity, another scenario enabled by the availability of
this technology may involve illicit economic purposes.
Among the potential applications of synthetic biology is
the production of ﬁne chemicals in a cheaper and easier
way than it is done today (Ro et al. 2006; Keasling 2008).
While most people would instantly think of pharmaceuti-
cals, bioplastic or biofuels, the range of chemical products
is not bound to moral norms. According to the United
Nations Ofﬁce on Drugs and Crime (UNODC), for exam-
ple, some 200 million people, or 5% of the world’s
population age 15–64, have used drugs at least once in the
last 12 months (UNODC 2005; UNODC 2007). Not to
forget that the size of the global illicit drug market is
substantial, with a value, measured at retail prices, higher
than the GDP of 88% of the countries in the world
(UNODC 2005). One of the ﬂagship examples of synthetic
biology is the production of anti-malaria cure artemisinin
in engineered yeast (Ro et al. 2006). This production way is
estimated to cut costs by a factor of 10 compared to the
traditional way of production, namely plantation of Arte-
misia annua and subsequent extraction of its biochemical
compounds. There is no reason to believe that full
biosynthesis of currently semi-synthetic drugs such as her-
oine or cocaine, or fully synthetic amphetamine-type
stimulants will not be possible and economically attractive
using the toolkit of synthetic biology in the near future.
Given, for example, that 2.8% of US adults are regular
consumersofcocainealone(UNODC2005)thefutureillicit
bio-economy could see some dramatic changes once the
technology to manufacture metabolisms a ´ la carte is out
there.
Biodefense
Biodefense has to be considered under the label of biose-
curity, not biosafety. There are, however, also biosafety
aspects involved. It is true that biodefense doesn’t deal
solely with synthetic biology, however, there is little doubt
that such a powerful new technology goes unnoticed in the
biodefense community. It is also worth remembering that
one of the ﬁrst viruses fully synthesized was the poliovirus
and the 1918 Spanish infuenza pandemic virus (Cello et al.
2002; Tumpej et al. 2005; Sharp 2005). Since the 9/11
event the funding for work on biodefense has dramatically
increased in the US. The US Government Civilian Biode-
fense Funding, between ﬁscal year 2001 and 2008 cost US
tax payers more than 39 billion US$ (Franco and Deitch
2007). Even within the US there are many voices ques-
tioning this kind of allocation of resources. Klotz (2007)
recently used basic risk assessment calculation to alert us to
the imbalance in funding and effort between biodefense,
‘‘the overrated threat’’, and endemic infectious disease ‘‘the
real killers’’. Anyway this issue is not solely restricted to
synthetic biology, synthetic biology could only accelerate
the ongoing situation.
The massive amount of money ﬂooded into biodefense
research, including construction of new biosafety level
(BSL) 3 and 4 facilities in the US and extensive research
with dangerous pathogens is prompting a safety risk to the
increasing number of biodefense researchers and commu-
nities around BSL 3 and 4 facilities (see ‘‘newcomers’’).
The number of BSL-4 laboratories in the US, for example,
has increased from 5, before 2001, to 15 in 2007. Also the
number of BSL 3 facilities has risen to a total of 1,356
(GAO 2007). The conclusion on accountability of these
BSL laboratories, presented by the United States Govern-
ment Accountability Ofﬁce, were particularly alarming
saying that ‘‘no single federal agency has the mission to
track and determine the risk associated with the expansion
of BSL-3 and BSL-4 labs in the United States, and no single
federal agency knows how many such labs there are in the
United States. Consequently, no one is responsible for
determining the aggregate risks associated with the
expansion of these high-containment labs.’’ (GAO 2007).
6 See: http://hacks.mit.edu/Hacks/misc/ethics.html or http://www.
stevenlevy.com/index.php/other-books/hackers
7 See protocol of the ﬁrst DIYbio meeting: http://openwetware.org/
wiki/DIYbio:Meeting_-_May_2008
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handling BSL 3 and 4 material are now working in bio-
defense research, and accidents in those facilities seem to
happen more frequently than one would think (see: Hecht
and MacKenzie 2005; MacKenzie 2007; GAO 2007;
Sunshine Project 2007; Aldhous 2008).
8 Local communi-
ties are already uneasy and sometimes even protesting
against new facilities (see e.g. Check 2006; Coleman
2006). Putting this altogether, there is no reason to believe
that synthetic biology should not ﬁnd its way into the
biodefense R&D and into the increasing number of BSL 3
and 4 laboratories, with their not always so satisfying
safety record, causing a notable increase in biosafety risk
for laboratory workers, surrounding communities and
beyond.
Safety for standardized bioparts
Research undertaken on standardized bioparts suggests that
it could be possible to have—one day—a toolbox of bio-
parts that can be easily assembled to devices and systems.
As R&D on standardized bioparts is continuing we will see
more and more parts, devices and systems with different
characteristics. If this concept proves to be successful it
would mean a tremendous simpliﬁcation in the design
process of living organisms, so that even high school stu-
dents could design their own pet bug (Dyson 2007). As
more parts become available in the Biobrick registry, and
as more people have general access to sequence speciﬁ-
cations and DNA synthesis, the task of enforcement
resulting from restricted access or practice will become
increasingly untenable (Carlson 2007b). As with any
toolbox, some combinations of parts, devices and systems
could raise biosafety concerns, especially when emergent
behaviour of novel biocircuits cannot be ruled out due to
the lack of sufﬁcient separation of functional units (such as
in integrated circuits) and the skyrocketing number of
possible interactions between those units.
9
• Parts: There might be a need to think about safety
standards when dealing with parts: Some parts could be
more of a safety problem than others, so different safety
categories could be invented for parts, and also for
devices and systems.
• Bio-circuits: a combination of otherwise safe parts, may
result in a gene circuit that exhibits characteristics that
are not safe. Is there any way to include e.g. a safety
check in bio-circuit design?
• ‘‘Pimp my chassis’’: a chassis
10 that is able to survive in
the soil, e.g. for bioremediation purposes (Sayler and
Ripp 2000; Cases and de Lorenzo 2005) has to be
treated differently from a chassis that can only survive
under certain laboratory conditions. Parts, device and
systems that happen to extend the environmental range
of a chassis, i.e. tolerance of a wider range of biotic and
abiotic conditions, should be considered in a special
safety category.
Working with parts, devices and systems in speciﬁc
chassis organisms open up new safety and security chal-
lenges, not yet covered by current biosafety and security
rules and guidelines. Although the idea of standardized
bioparts is to outrule emergent properties, it is likely that
not all emergent properties can be foreseen. Some emerg-
ing questions
11 are:
• Different categories: is it necessary to put parts, devices
and systems into different safety or security categories?
• Biosafety clearinghouse: how can a safety issue be
reported that was discovered in a certain bio-circuit and
that was not foreseen (emergent) so other people can
learn from that experience?
• Provision: how can safety and security aspects be
integrated into the design process so the design
software automatically informs the designer in case
the newly designed circuit exhibits certain safety (or
security) problems?
• Design assessment: do we need a new risk assessment
tool to ensure safety (and security) of parts-based bio-
circuits?
Conclusion
A rarely mentioned challenge for the safe and constructive
development of synthetic biology is the ongoing diffusion
of the technology, knowledge and capabilities beyond the
professional biotechnology community. This would, ﬁrst of
all, involve engineers and computer scientists, but later on
this will include also other groups beyond the academic
8 E.g. failure to report to CDC exposures to select agents by Texas
A&M University (TAMU); power outage at CDC’s new BSL-4 lab in
Atlanta, Georgia; and a release of foot-and-mouth disease virus at
Pirbright in the United Kingdom. (GAO 2007; Sunshine-Project 2007)
9 In theory a relatively small number of 20 bioparts may result in up
to 20! (20*19*18*…*2*1) or about 10
18 possible interactions making
it difﬁcult to calculate all interactions and completely outrule
emergent behaviour with the current approach. See discussion on
the Biobricks Standard mailing list: http://biobricks.org/pipermail/
standards_biobricks.org/2008-February/000033.html and http://biob
ricks.org/pipermail/standards_biobricks.org/2008-May/thread.html
10 A chassis is a kind of minimal cell that can be used to incooperate
bio-parts, -devices and -systems.
11 These safety questions have previously been posted by the author
at the biobricks standardisation mailing list, see: http://biobricks.org/
pipermail/standards_biobricks.org/2008-February/date.html
4 M. Schmidt
123and professional circle such as hackers and school kids, and
maybe even less benign individuals and organisations
active in the illicit knowledge based bio-economy. Finally
the massive support and growth of the (US) biodefense
research community and their activities also raise some
serious safety issues, both for the biodefense workers and
the surrounding communities. The growing repositories of
the biobricks foundation dealing with standardized bioparts
also opens particular biosafety questions that need to be
addressed as more and more people start to use them.
Synthetic biology could well be the next industrial
revolution deﬁning the 21st century, and if so it is abso-
lutely necessary to consider the implications of its
diffusion, well before they materialize and devise possible
strategies to minimize safety risks (NSABB 2006, 2007;
Schmidt 2006; Tucker and Zilinskas 2006). There is,
however, no silver bullet to solve these complex issues, and
righteous prohibition is not an option if we want to harvest
the beneﬁts of synthetic biology. And of course a cornu-
copian anything-goes mentality isn’t the answer either.
Some scientists argue that certain key technologies in
synthetic biology (such as synthesis of DNA) will even-
tually be controlled by fewer and more efﬁcient companies,
automatically creating bottlenecks for regulation and
licensing (Bhattacharjee 2007;B u ¨gl et al. 2007). Such a
development can be compared to the electronic industry
where nowadays only a handful of companies produce
computer chips.
12 This economic and technological con-
centration process would on the one hand easily solve the
problem of out-of-control experiments, but on the other
hand would limit the ‘‘democratic domestication’’ of bio-
technology (Dyson 2007). (Promoting safety and security
standards you might ﬁnd yourselves unintentional aligned
with people with vested interests in the monopolisation of
key technologies in synthetic biology.)
‘‘Domesticated biotechnology, once it gets into the
hands of housewives and children, will give us an
explosion of diversity of new living creatures, rather
than the monoculture crops that the big corporations
prefer. […] The ﬁnal step in the domestication of
biotechnology will be biotech games, designed like
computer games for children down to kindergarten
age but played with real eggs and seeds rather than
with images on a screen. […] These games will be
messy and possibly dangerous. Rules and regulations
will be needed to make sure that our kids do not
endanger themselves and others.’’
Freeman Dyson 2007
13
There is, however, no ready-to-use recipe or toolbox we
can apply to minimize the risks of a biotechnology that one
day could be so easy to use that everybody can design their
own organisms. Failing to address the challenges posed by
diffusing the technology, knowledge and capabilities of
synthetic biology, might ultimately lead to a situation
where we cannot go back and close ‘‘Pandora’s box’’. We
should better start to think about it now.
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